Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
Read More
Merck’s immunotherapy Keytruda has been approved by US regulators to treat both adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
Read More
An analysis of data from a Phase II study of Merck & Co’s immunotherapy Keytruda has demonstrated high response rates in heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Read More
